Pyk2-derived peptides for inhibiting invadopodia-mediated cancer metastasis
AssigneeBar-Ilan University
InventorsHava GIL-HENN, Jordan CHILL
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated Pyk2-derived peptide comprising a consensus proline-rich region 2 (PRR2) sequence, wherein the consensus PRR2 sequence is PxxPx(R/K)P(K/R)(Y/W/F) in which “x” stands for any amino acid; and the peptide is capable of inhibiting metastasis by binding to a Src homology 3 (SH3) domain of cortactin. The present invention further provides methods of treating cancer and for preventing or inhibiting cancer invasion and/or metastasis by administering the isolated Pyk2-derived peptide of the invention, optionally in combination with an anti-cancer agent.
Claims20
An isolated Pyk2-derived peptide comprising a consensus proline-rich region 2 (PRR2) sequence, wherein the consensus PRR2 sequence is PxxPx(R/K)P(K/R)(Y/W/F) in which “x” stands for any amino acid;
- and the peptide is capable of inhibiting metastasis by binding to a Src homology 3 (SH3) domain of cortactin.
Dependencies are inferred from the claim text.